Over the last eight months, the US Federal Trade Commission (FTC) has focused on what it characterizes as “improper” Orange Book listings and the impacts of such listings on generic entry....more
2019 was a banner year for billion-dollar life sciences M&A transactions. A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019,...more
Biologic drug makers will soon have to alert the Federal Trade Commission and Department of Justice of agreements, including patent litigation settlements, they reach with biosimilar applicants. The new reporting requirement...more
Attention in the US during 2016 will be on the presidential campaign, and the election in November will bring a change in the "antitrust guard" at the top of the DOJ and FTC – even if a Democrat wins – that will drive the...more
1/12/2016
/ China ,
Corporate Counsel ,
Criminal Penalties ,
Department of Justice (DOJ) ,
Disgorgement ,
Drug Pricing ,
EU ,
European Commission ,
Federal Trade Commission (FTC) ,
FRAND ,
Mergers ,
MOFCOM ,
Patent Assertion Entities ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Price-Fixing ,
Standard Essential Patents ,
Technology Sector
Recent antitrust challenges to pharmaceutical companies' efforts to transition patients from drugs nearing the end of their patent life to next-generation drugs have increased the risk of pursuing such "product hopping"...more